Assay reveals potency of neutralising antibodies in COVID-19 patients
Researchers have shown that neutralising antibodies developed in COVID-19 patients were less potent if from those with severe or fatal disease.
List view / Grid view
Researchers have shown that neutralising antibodies developed in COVID-19 patients were less potent if from those with severe or fatal disease.
Scientists have created a prognostic classification model which uses biomarkers to help predict an individual’s risk of developing severe COVID-19 symptoms.
UK Health Secretary Matt Hancock has said there is a mutated form of SARS-CoV-2 that may be causing a rise in infections in South East England.
New research has demonstrated in mouse models that the SHP-1 protein limits the capacity of dendritic cells, making it a target for a leishmaniasis vaccine.
The Junior Editors of Drug Target Review, Victoria Rees and Hannah Balfour, discuss some of the most noteworthy news and announcements from this year.
Two new studies suggest that SARS-CoV-2-specific IgA antibodies are more neutralising and therefore COVID-19 vaccines should encourage an IgA response.
Next-generation sequencing will be employed to study 1,500 plasma proteins in participants, according to UK Biobank.
Study suggests reducing the expression of the methyl-CpG-binding domain 2 (MBD2) protein on macrophages could be a viable therapeutic strategy for lung fibrosis.
The new study shows how SARS-CoV-2 significantly remodels cellular processes in just an hour and identifies potential drug targets and therapeutics for COVID-19.
The novel probes, known as positive controls, could make it easier to validate rapid, point-of-care diagnostic tests for COVID-19 across the globe.
According to researchers, the more small tau protein variants expressed by neurons, the slower neurofibrillary tangles form.
An artificial intelligence (AI) system called AlphaFold has been developed to effectively predict protein structures and folding.
Professor Laurence D Hurst explains why understanding the nucleotide mutations in viruses, including SARS-CoV-2, can have significant implications for vaccine design.
By combining machine learning and T-cell engineering researchers were able to develop cell therapies that can selectively and effectively target and destroy solid tumours.
Researchers demonstrate that the CARD8 protein plays a key role in regulating the inflammation that causes atherosclerosis and other inflammatory diseases.